The U.S. Food and Drug Administration granted accelerated approval for the Alzheimer’s disease drug lecanemab (Leqembi). The drug, a monoclonal antibody, binds to amyloid beta in the brain. An 18-month study published in the New England Journal of Medicine1 found Leqembi reduced markers of amyloid in early Alzheimer’s disease and led to “moderately less decline”… Read More »
New research in humans and mice identifies a particular signaling molecule that can help modify inflammation and the immune system to protect against Alzheimer’s disease. The work, which was led by investigators at Harvard-affiliated Massachusetts General Hospital (MGH), is published in Nature. Cognitive decline associated with Alzheimer’s disease develops when neurons begin to die. “Neuron death… Read More »
Aduhelm by Biogen Source: Biogen The FDA’s approval of Biogen‘s Alzheimer’s drug Aduhelm was a landmark moment in the life of Dr. Paul Aisen. The director of the Alzheimer’s Therapeutic Research Institute at USC has spent the past three decades focused on treating the neurodegenerative disease, and in recent years helped shepherd this particular drug… Read More »
FDA Grants Accelerated Approval for Aduhelm (aducanumab-avwa) for the Treatment of Alzheimer’s Disease CAMBRIDGE, Mass. and TOKYO, June 07, 2021 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Aduhelm™ (aducanumab-avwa) as the first and only Alzheimer’s… Read More »
The Food and Drug Administration has approved the Alzheimer’s drug aducanumab despite controversy over whether there is sufficient evidence to support the drug’s effectiveness. Aducanumab is the first Alzheimer’s drug approved by the FDA in almost 20 years. It has been developed by the company Biogen in collaboration with a Japanese firm Eisai. It is… Read More »